Albert Labs International (FRA:VB50) LT-Debt-to-Total-Asset: 0.16 (As of Sep. 2023)


What is Albert Labs International LT-Debt-to-Total-Asset?

Albert Labs International FRA:VB50 LT-Debt-to-Total-Asset is 0.16 as of Sep. 2023.

LT Debt to Total Assets is a measurement representing the percentage of a corporation's assets that are financed with loans and financial obligations lasting more than one year. The ratio provides a general measure of the financial position of a company, including its ability to meet financial requirements for outstanding loans. It is calculated as a company's Long-Term Debt & Capital Lease Obligationdivide by its Total Assets. Albert Labs International's long-term debt to total assests ratio for the quarter that ended in Sep. 2023 was 0.16.

Albert Labs International's long-term debt to total assets ratio increased from Sep. 2022 (0.00) to Sep. 2023 (0.16). It may suggest that Albert Labs International is progressively becoming more dependent on debt to grow their business.

Albert Labs International  (FRA:VB50) LT-Debt-to-Total-Asset Explanation

LT Debt to Total Asset is a measurement representing the percentage of a corporation's assets that are financed with loans and financial obligations lasting more than one year. The ratio provides a general measure of the financial position of a company, including its ability to meet financial requirements for outstanding loans. A year-over-year decrease in this metric would suggest the company is progressively becoming less dependent on debt to grow their business.

Albert Labs International LT-Debt-to-Total-Asset Related Terms

Albert Labs International LT-Debt-to-Total-Asset Historical Data

* Premium members only.

The historical data trend for Albert Labs International's LT-Debt-to-Total-Asset can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Albert Labs International LT-Debt-to-Total-Asset Chart

Albert Labs International Annual Data
Trend Dec21 Dec22
LT-Debt-to-Total-Asset
0.00 0.00

Albert Labs International Quarterly Data
Mar21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23
LT-Debt-to-Total-Asset Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.16

Albert Labs International LT-Debt-to-Total-Asset Calculation

Albert Labs International's Long-Term Debt to Total Asset Ratio for the fiscal year that ended in Dec. 2022 is calculated as

LT Debt to Total Assets (A: Dec. 2022 )=Long-Term Debt & Capital Lease Obligation (A: Dec. 2022 )/Total Assets (A: Dec. 2022 )
=0/0.114
=

Albert Labs International's Long-Term Debt to Total Asset Ratio for the quarter that ended in Sep. 2023 is calculated as

LT Debt to Total Assets (Q: Sep. 2023 )=Long-Term Debt & Capital Lease Obligation (Q: Sep. 2023 )/Total Assets (Q: Sep. 2023 )
=0.007/0.045
=

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about LT-Debt-to-Total-Asset →
What does a LT-Debt-to-Total-Asset of 0.16 mean?
Albert Labs International (FRA:VB50) has a LT-Debt-to-Total-Asset of 0.16 as of Sep. 2023. Long-term Debt to Total Asset ratio is the ratio of total long-term debt to total assets. View historical data on Albert Labs International and its competitors.
Is Albert Labs International's LT-Debt-to-Total-Asset too high?
Albert Labs International's current LT-Debt-to-Total-Asset is 0.16.
How does Albert Labs International's LT-Debt-to-Total-Asset compare to VRTX and REGN?
Albert Labs International's LT-Debt-to-Total-Asset of 0.16 can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good LT-Debt-to-Total-Asset for a Biotechnology company?
A good LT-Debt-to-Total-Asset depends on the Biotechnology industry context. However, LT-Debt-to-Total-Asset should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high LT-Debt-to-Total-Asset mean?
A high LT-Debt-to-Total-Asset can signal that a stock is expensive relative to its fundamentals. Long-term Debt to Total Asset ratio is the ratio of total long-term debt to total assets. View historical data on Albert Labs International and its competitors. Albert Labs International's current LT-Debt-to-Total-Asset is 0.16. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Albert Labs International stock overvalued right now?
Albert Labs International (FRA:VB50) has a current LT-Debt-to-Total-Asset of 0.16. The current LT-Debt-to-Total-Asset is 0.16. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is LT-Debt-to-Total-Asset calculated?
LT-Debt-to-Total-Asset is calculated from a company's financial statements. For Albert Labs International (FRA:VB50), the current LT-Debt-to-Total-Asset is 0.16 as of Sep. 2023. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Albert Labs International Business Description

Address 201-6996 Merritt Avenue, Burnaby, BC, CAN, V5J 4R6
Albert Labs International Corp is a laboratory-based, clinical research, and drug development enterprise addressing mental health care needs. The company is focusing on Real World Evidence (RWE) the company will initially look to commercialize its mycelium-based KRN-101 medicine and treatment with the help of a clinical pathway.